XSWX
DOCM
Market cap785mUSD
Oct 09, Last price
13.32CHF
1D
5.70%
1Q
53.74%
IPO
-91.09%
Name
Zur Rose Group AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DocMorris AG, an enterprise headquartered in Frauenfeld, Switzerland, and founded in 1993, operates a dual business model encompassing e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods. Its market reach extends both within Switzerland and across international borders. The company's diverse offerings include consumer health, beauty, and personal care items, alongside services focused on medication management. Furthermore, DocMorris AG maintains physical pharmacy locations. It directly supplies its products to various clients, including medical professionals, online mail-order pharmacies, and individual consumers, utilizing several distinct brands such as Zur Rose, PromoFarma, TeleClinic, and DocMorris. The organization was initially known as Zur Rose AG before it changed its name to Zur Rose Group AG in May 2015.
Related entities
Subsidiaries
DocMorris Finance B.V.
Key people
Stefan Feuerstein
Non-Executive Chairman of the Board of Directors
Thomas Schneider
Non-Executive Vice Chairman of the Board of Directors
Non-Executive Member of the Board of Directors · since 2019
Headquarters & legal address
Walzmühlestrasse 49
Frauenfeld, TG 8500
CH
Frauenfeld, TG 8500
CH
Previous name
Zur Rose Group AG
Other language
DocMorris Ltd
Other language
DocMorris SA
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||